Coverart for item
The Resource From immunotherapy of cancer to the discovery of kidney cancer genes : a personal history, Berton Zbar, (electronic book)

From immunotherapy of cancer to the discovery of kidney cancer genes : a personal history, Berton Zbar, (electronic book)

Label
From immunotherapy of cancer to the discovery of kidney cancer genes : a personal history
Title
From immunotherapy of cancer to the discovery of kidney cancer genes
Title remainder
a personal history
Statement of responsibility
Berton Zbar
Creator
Subject
Language
eng
Summary
I had the good fortune to work at the National Cancer Institute from 1965 to 2005. The National Cancer Institute provided an environment that permitted my curiosity to flourish. Colleagues, particularly Marston Linehan, were essential to performance of the work. The work described in this manuscript was performed during a period of rapid advances in genetics. I was able to apply my clinical training and new genetic tools to study human kidney cancer. With the support of the National Cancer Institute, I was able to canvas physicians throughout the United States and Canada for referrals of families with multiple members affected with renal cancer. I was able to visit these families in their communities and determine the clinical and genetic features of their hereditary susceptibility to renal cancer, and to bring these families to Bethesda for comprehensive examinations. Using DNA analytic tools, we were able to identify several tumor suppressor genes that play major roles in the pathogenesis of human renal carcinoma thus opening up new fields for biochemical research into the pathogenesis of human renal carcinoma
Member of
Cataloging source
CaBNVSL
http://library.link/vocab/creatorName
Zbar, Berton
Dewey number
616.99461
Illustrations
illustrations
Index
no index present
LC call number
RC280.K5
LC item number
Z324 2013
Literary form
non fiction
Nature of contents
  • dictionaries
  • abstracts summaries
  • bibliography
http://library.link/vocab/subjectName
  • Renal cell carcinoma
  • Cancer
  • Carcinoma, Renal Cell
  • Neoplasms
Target audience
  • adult
  • specialized
Label
From immunotherapy of cancer to the discovery of kidney cancer genes : a personal history, Berton Zbar, (electronic book)
Instantiates
Publication
Bibliography note
Includes bibliographical references (p. 65-75)
Color
multicolored
Contents
  • 1. Introduction --
  • 2. From immunotherapy of cancer to genetic studies of lung and kidney cancer --
  • 3. Preliminary genetic studies -- 3.1 Detection of chromosomal loss in human clear cell renal carcinomas -- 3.2 Human renal carcinoma and human small cell lung carcinoma are both characterized by loss of chromosome 3p --
  • 4. von Hippel-Lindau disease -- 4.1 Recruitment of families with von Hippel-Lindau disease -- 4.2 Evaluation of members of families affected with von Hippel-Lindau disease -- 4.3 Linkage analysis -- 4.4 Pulsed field gel electrophoresis -- 4.5 The VHL gene is mutated in most sporadic clear cell renal carcinomas -- 4.6 The VHL family alliance -- 4.7 The VHL protein -- 4.8 Therapy for metastatic clear cell renal carcinoma -- 4.9 Summary of the VHL gene discovery effort at the National Cancer Institute -- 4.10 Support of the VHL program by the National Cancer Institute --
  • 5. Chromosome 3 translocation families -- 5.1 Genetic basis of the chromosome 3;8 translocation family susceptibility to renal cancer -- 5.2 VHL, SETD2, and PBRM1 mutations associated with renal cancer --
  • 6. Hereditary papillary renal carcinoma -- 6.1 Discovery of the met proto-oncogene as the gene responsible for hereditary papillary renal carcinoma -- 6.2 Germline mutations in the met proto-oncogene occur at specific residues in the tyrosine kinase domain of the protein -- 6.3 Infrequent somatic mutations in the met proto-oncogene in sporadic papillary renal carcinomas -- 6.4 Difficulties in diagnosis of hereditary papillary renal carcinoma -- 6.5 Duplication of the chromosome with the mutant met proto-oncogene in HPRC renal tumors -- 6.6 Treatment of renal cancer with inhibitors of the met proto-oncogene -- 6.7 Genetic heterogeneity of familial papillary renal carcinoma -- 6.8 A curious coincidence --
  • 7. The open door policy in the urologic oncology clinic of the National Cancer Institute Birt-Hogg-Dube syndrome --
  • 8. The Birt-Hogg-Dube syndrome -- 8.1 Strategy to determine whether renal tumors were a manifestation of the Birt-Hogg-Dube syndrome -- 8.2 Design of field trips to members of families affected with the Birt-Hogg-Dube syndrome -- 8.3 Statistical analysis of association between fibrofolliculomas and renal cancer and between fibrofolliculomas and spontaneous pneumothorax -- 8.4 Combined traveling National Cancer Institute dermatology clinics to study genodermatoses -- 8.5 Genodermatoses associated with renal carcinoma. The Birt-Hogg-Dube syndrome -- 8.6 Function of the Birt-Hogg-Dube protein, folliculin -- 8.7 The renal tumors in the Birt-Hogg-Dube syndrome have a characteristic unique morphology -- 8.8 Genetic heterogeneity of familial renal oncocytomas -- 8.9 Mouse and other animal models of BHD -- 8.10 Biochemical pathways regulated by folliculin --
  • 9. Hereditary leiomyoma renal cell carcinoma -- 9.1 Genodermatoses associated with renal carcinoma. Hereditary leiomyoma renal cell carcinoma (HLRCC). Fumarate hydratase gene mutations -- 9.2 Renal tumor pathology in hereditary leiomyoma renal cell carcinoma --
  • 10. Succinate dehydrogenase gene mutations and renal carcinoma --
  • 11. Tuberous schlerosis and renal carcinoma --
  • 12. Affection status and linkage analysis --
  • 13. Familial renal carcinoma and genome-wide association studies --
  • 14. Revisiting the National Cancer Institute urologic oncology branch collection of renal cancer families to identify germline mutations in renal carcinoma genes in previously accessioned families. Time between family accession and germline mutation detection. Detection of germline mutations in families with single, living affected individuals -- 14.1 Non-Mendelian renal cell carcinoma -- 14.1.1 Papillary renal carcinoma --
  • 15. Recent discoveries in human renal cancer genetics -- 15.1 PBRM1, BAP1, and SETD2 -- 15.2 Intratumor heterogeneity of clear cell renal carcinomas --
  • 16. Use of next-generation DNA sequencing to study the genetic basis of human renal cell carcinomas -- 16.1 Biochemical pathways in human renal carcinogenesis --
  • 17. Conclusion -- References
Control code
201303GBD003
Dimensions
unknown
Extent
1 electronic text (ix, 75 p.)
File format
multiple file formats
Form of item
online
Isbn
9781615044269
Isbn Type
(pbk)
Issn
2168-4022
Other control number
10.4199/C00074ED1V01Y201303GBD003
Other physical details
ill., digital file.
Reformatting quality
access
Specific material designation
remote
System details
System requirements: Adobe Acrobat reader
Label
From immunotherapy of cancer to the discovery of kidney cancer genes : a personal history, Berton Zbar, (electronic book)
Publication
Bibliography note
Includes bibliographical references (p. 65-75)
Color
multicolored
Contents
  • 1. Introduction --
  • 2. From immunotherapy of cancer to genetic studies of lung and kidney cancer --
  • 3. Preliminary genetic studies -- 3.1 Detection of chromosomal loss in human clear cell renal carcinomas -- 3.2 Human renal carcinoma and human small cell lung carcinoma are both characterized by loss of chromosome 3p --
  • 4. von Hippel-Lindau disease -- 4.1 Recruitment of families with von Hippel-Lindau disease -- 4.2 Evaluation of members of families affected with von Hippel-Lindau disease -- 4.3 Linkage analysis -- 4.4 Pulsed field gel electrophoresis -- 4.5 The VHL gene is mutated in most sporadic clear cell renal carcinomas -- 4.6 The VHL family alliance -- 4.7 The VHL protein -- 4.8 Therapy for metastatic clear cell renal carcinoma -- 4.9 Summary of the VHL gene discovery effort at the National Cancer Institute -- 4.10 Support of the VHL program by the National Cancer Institute --
  • 5. Chromosome 3 translocation families -- 5.1 Genetic basis of the chromosome 3;8 translocation family susceptibility to renal cancer -- 5.2 VHL, SETD2, and PBRM1 mutations associated with renal cancer --
  • 6. Hereditary papillary renal carcinoma -- 6.1 Discovery of the met proto-oncogene as the gene responsible for hereditary papillary renal carcinoma -- 6.2 Germline mutations in the met proto-oncogene occur at specific residues in the tyrosine kinase domain of the protein -- 6.3 Infrequent somatic mutations in the met proto-oncogene in sporadic papillary renal carcinomas -- 6.4 Difficulties in diagnosis of hereditary papillary renal carcinoma -- 6.5 Duplication of the chromosome with the mutant met proto-oncogene in HPRC renal tumors -- 6.6 Treatment of renal cancer with inhibitors of the met proto-oncogene -- 6.7 Genetic heterogeneity of familial papillary renal carcinoma -- 6.8 A curious coincidence --
  • 7. The open door policy in the urologic oncology clinic of the National Cancer Institute Birt-Hogg-Dube syndrome --
  • 8. The Birt-Hogg-Dube syndrome -- 8.1 Strategy to determine whether renal tumors were a manifestation of the Birt-Hogg-Dube syndrome -- 8.2 Design of field trips to members of families affected with the Birt-Hogg-Dube syndrome -- 8.3 Statistical analysis of association between fibrofolliculomas and renal cancer and between fibrofolliculomas and spontaneous pneumothorax -- 8.4 Combined traveling National Cancer Institute dermatology clinics to study genodermatoses -- 8.5 Genodermatoses associated with renal carcinoma. The Birt-Hogg-Dube syndrome -- 8.6 Function of the Birt-Hogg-Dube protein, folliculin -- 8.7 The renal tumors in the Birt-Hogg-Dube syndrome have a characteristic unique morphology -- 8.8 Genetic heterogeneity of familial renal oncocytomas -- 8.9 Mouse and other animal models of BHD -- 8.10 Biochemical pathways regulated by folliculin --
  • 9. Hereditary leiomyoma renal cell carcinoma -- 9.1 Genodermatoses associated with renal carcinoma. Hereditary leiomyoma renal cell carcinoma (HLRCC). Fumarate hydratase gene mutations -- 9.2 Renal tumor pathology in hereditary leiomyoma renal cell carcinoma --
  • 10. Succinate dehydrogenase gene mutations and renal carcinoma --
  • 11. Tuberous schlerosis and renal carcinoma --
  • 12. Affection status and linkage analysis --
  • 13. Familial renal carcinoma and genome-wide association studies --
  • 14. Revisiting the National Cancer Institute urologic oncology branch collection of renal cancer families to identify germline mutations in renal carcinoma genes in previously accessioned families. Time between family accession and germline mutation detection. Detection of germline mutations in families with single, living affected individuals -- 14.1 Non-Mendelian renal cell carcinoma -- 14.1.1 Papillary renal carcinoma --
  • 15. Recent discoveries in human renal cancer genetics -- 15.1 PBRM1, BAP1, and SETD2 -- 15.2 Intratumor heterogeneity of clear cell renal carcinomas --
  • 16. Use of next-generation DNA sequencing to study the genetic basis of human renal cell carcinomas -- 16.1 Biochemical pathways in human renal carcinogenesis --
  • 17. Conclusion -- References
Control code
201303GBD003
Dimensions
unknown
Extent
1 electronic text (ix, 75 p.)
File format
multiple file formats
Form of item
online
Isbn
9781615044269
Isbn Type
(pbk)
Issn
2168-4022
Other control number
10.4199/C00074ED1V01Y201303GBD003
Other physical details
ill., digital file.
Reformatting quality
access
Specific material designation
remote
System details
System requirements: Adobe Acrobat reader

Library Locations

Processing Feedback ...